OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Development of Effective Siglec-9 Antibodies Against Cancer
Jun Hui Shawn Wang, Nan Jiang, Amit Jain, et al.
Current Oncology Reports (2022) Vol. 25, Iss. 1, pp. 41-49
Open Access | Times Cited: 7
Jun Hui Shawn Wang, Nan Jiang, Amit Jain, et al.
Current Oncology Reports (2022) Vol. 25, Iss. 1, pp. 41-49
Open Access | Times Cited: 7
Showing 7 citing articles:
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 23
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 23
Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling
Unai Atxabal, Corwin M. Nycholat, Johannes M. Pröpster, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 2, pp. 483-496
Open Access | Times Cited: 5
Unai Atxabal, Corwin M. Nycholat, Johannes M. Pröpster, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 2, pp. 483-496
Open Access | Times Cited: 5
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
Vasyl Eisenberg, Shiran Hoogi, Erel Katzman, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 10, pp. 1380-1391
Closed Access | Times Cited: 4
Vasyl Eisenberg, Shiran Hoogi, Erel Katzman, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 10, pp. 1380-1391
Closed Access | Times Cited: 4
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024)
Qiaohong Geng, Juanjuan Xu, Cheng Du, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Qiaohong Geng, Juanjuan Xu, Cheng Du, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
Ramya Ayyalasomayajula, Mare Čudić
Cancers (2024) Vol. 16, Iss. 7, pp. 1334-1334
Open Access | Times Cited: 3
Ramya Ayyalasomayajula, Mare Čudić
Cancers (2024) Vol. 16, Iss. 7, pp. 1334-1334
Open Access | Times Cited: 3
Prognostic and immune infiltration implications of SIGLEC9 in SKCM
Yang Peipei, Yunhui Jiang, Rong Chen, et al.
Diagnostic Pathology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 1
Yang Peipei, Yunhui Jiang, Rong Chen, et al.
Diagnostic Pathology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 1
High SIGLEC9 Expression Levels in Cervical Cancer Correlate with Immune Cell Infiltration
B. Wang, Yuejie Zhu, Zhenyu Ru, et al.
Research Square (Research Square) (2023)
Open Access
B. Wang, Yuejie Zhu, Zhenyu Ru, et al.
Research Square (Research Square) (2023)
Open Access
